Literature DB >> 16041261

Characteristic pattern of chromosomal imbalances in posttransplantation lymphoproliferative disorders: correlation with histopathological subcategories and EBV status.

Hélène A Poirel1, Alain Bernheim, Anouck Schneider, Mounira Meddeb, Sylvain Choquet, Véronique Leblond, Frédéric Charlotte, Frédéric Davi, Danielle Canioni, Elizabeth Macintyre, Marie-France Mamzer-Bruneel, Isabelle Hirsch, Olivier Hermine, Antoine Martin, Pascale Cornillet-Lefebvre, Martine Patey, Olivier Toupance, Jean-Louis Kémény, Patrice Deteix, Martine Raphaël.   

Abstract

BACKGROUND: Posttransplantation lymphoproliferative disorders (PTLDs) are a spectrum of lymphoid proliferations, occurring in immunosuppressed organ transplant recipients. They comprise early lesions, polymorphic (P-PTLD), monomorphic (M-PTLD), and Hodgkin/Hodgkin-like lymphoma PTLD (HL-PTLD) lesions. Most of them are associated with Epstein-Barr virus (EBV). Little is known about their genetic changes.
MATERIALS AND METHODS: We have studied 35 PTLDs[7 P-PTLDs (3/7 polyclonal IgH), 26 M-PTLDs (22 B-cell PTLD, 4 T-cell PTLD), 2 HL-PTLDs], using comparative genomic hybridization (CGH), a DNA-based technique allowing a screening of chromosomal imbalances without needing cultured cells. RESULTS.: Overall incidence of chromosomal imbalances: 51.5 %. The most frequent gains involved 8q24, 3q27 [4 cases each]; 2p24p25, 5p, 9q22q34, 11, 12q22q24, 14q32, 17q, 18q21 [2 cases each]. Nonrandom losses were 17p13 [4 cases]; 1p36, 4q [3 cases each]; 17q23q25, Xp [2 cases each]. Three high-level amplifications were detected: 4p16, 9p22p24, 18q21q23. In this latter imbalance, involvement of Bcl2 has been confirmed by FISH. The nonrandom CGH imbalances occurring in M-PTLD are usually described in lymphomas of immunocompetent patients and contain genes known to be involved in lymphomagenesis, while genomic abnormalities detected in half cases of EBV positive P-PTLD are mostly unknown.
CONCLUSION: This study reported nonrandom chromosomal imbalances in PTLD and also identified early genomic alterations in EBV positive P-PTLD. These results raise two questions: the role of such lesions in the development and progression of those EBV induced-lymphoproliferations and their clinical significance especially in P-PTLD.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16041261     DOI: 10.1097/01.tp.0000163288.98419.0d

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  22 in total

1.  Functional interplay of Epstein-Barr virus oncoproteins in a mouse model of B cell lymphomagenesis.

Authors:  Thomas Sommermann; Tomoharu Yasuda; Jonathan Ronen; Tristan Wirtz; Timm Weber; Ulrike Sack; Rebecca Caeser; Jingwei Zhang; Xun Li; Van Trung Chu; Anna Jauch; Kristian Unger; Daniel J Hodson; Altuna Akalin; Klaus Rajewsky
Journal:  Proc Natl Acad Sci U S A       Date:  2020-06-10       Impact factor: 11.205

2.  Constitutive AP-1 activity and EBV infection induce PD-L1 in Hodgkin lymphomas and posttransplant lymphoproliferative disorders: implications for targeted therapy.

Authors:  Michael R Green; Scott Rodig; Przemyslaw Juszczynski; Jing Ouyang; Papiya Sinha; Evan O'Donnell; Donna Neuberg; Margaret A Shipp
Journal:  Clin Cancer Res       Date:  2012-01-23       Impact factor: 12.531

Review 3.  Post-transplantation lymphoproliferative disorder after haematopoietic stem cell transplantation.

Authors:  Francesco Pegoraro; Claudio Favre
Journal:  Ann Hematol       Date:  2021-02-06       Impact factor: 3.673

Review 4.  Using Epstein-Barr viral load assays to diagnose, monitor, and prevent posttransplant lymphoproliferative disorder.

Authors:  Margaret L Gulley; Weihua Tang
Journal:  Clin Microbiol Rev       Date:  2010-04       Impact factor: 26.132

Review 5.  Avoiding pitfalls: what an endoscopist should know in liver transplantation--part II.

Authors:  Sharad Sharma; Ahmet Gurakar; Cemalettin Camci; Nicolas Jabbour
Journal:  Dig Dis Sci       Date:  2008-12-17       Impact factor: 3.199

6.  c-Myc and Rel/NF-kappaB are the two master transcriptional systems activated in the latency III program of Epstein-Barr virus-immortalized B cells.

Authors:  Nathalie Faumont; Stéphanie Durand-Panteix; Martin Schlee; Sebastian Grömminger; Marino Schuhmacher; Michael Hölzel; Gerhard Laux; Reinhard Mailhammer; Andreas Rosenwald; Louis M Staudt; Georg W Bornkamm; Jean Feuillard
Journal:  J Virol       Date:  2009-03-04       Impact factor: 5.103

7.  B-Cell and Classical Hodgkin Lymphomas Associated With Immunodeficiency: 2015 SH/EAHP Workshop Report-Part 2.

Authors:  Daphne de Jong; Margaretha G M Roemer; John K C Chan; John Goodlad; Dita Gratzinger; Amy Chadburn; Elaine S Jaffe; Jonathan Said; Yasodha Natkunam
Journal:  Am J Clin Pathol       Date:  2017-02-01       Impact factor: 2.493

8.  EBV-Positive B-Cell Proliferations of Varied Malignant Potential: 2015 SH/EAHP Workshop Report-Part 1.

Authors:  Yasodha Natkunam; John R Goodlad; Amy Chadburn; Daphne de Jong; Dita Gratzinger; John K C Chan; Jonathan Said; Elaine S Jaffe
Journal:  Am J Clin Pathol       Date:  2017-02-01       Impact factor: 2.493

9.  Screening for residual disease in pediatric burkitt lymphoma using consensus primer pools.

Authors:  Melissa Agsalda; Ian Kusao; David Troelstrup; Bruce Shiramizu
Journal:  Adv Hematol       Date:  2009-04-15

Review 10.  Molecular pathogenesis of B-cell posttransplant lymphoproliferative disorder: what do we know so far?

Authors:  J Morscio; D Dierickx; T Tousseyn
Journal:  Clin Dev Immunol       Date:  2013-04-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.